BIOVENTIX PLC — Director's Dealing 2014

Oct 22, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Director dealings

PR Newswire

London, October 22

                             Bioventix plc                        ("Bioventix" or the "Company")                               Director dealingsBioventix plc (AIM: BVXP) was notified on 22 October 2014 that on the same day,due to institutional investor demand, the following directors dealt in theordinary shares of 5 pence each ("Ordinary Shares") in the Company:Name       Position         Type of       Number    Price    Ordinary  Percentage                            transaction       of      per  shares and of Ordinary                                        Ordinary Ordinary      voting  Shares and                                          Shares    Share rights held      voting                                                  (pence)   following rights held                                                                  the   following                                                          transaction         the                                                                      transactionIan        Non-Executive    Disposal      8,000\*    655.0      32,000         0.6Nicholson  ChairmanPeter      Chief Executive  Disposal    80,000\*\*    655.0     761,176        15.1Harrison\*    4,000 of which were held in the name of his wife\*\*   25,000 of which were held in the name of his wifeFor further information please contact:Bioventix plc                                         Tel: 01252 728 001Peter Harrison             Chief Executive OfficerfinnCap Ltd                                           Tel: 020 7220 0500Geoff Nash/Simon Hicks     Corporate FinanceSteve Norcross             Corporate BrokingAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.